Skip to main content
. 2022 Apr 12;10:851453. doi: 10.3389/fped.2022.851453

Figure 1.

Figure 1

A survival analysis was conducted to evaluate difference (A) in the time to achieve remission and (B) in the time to first relapse after remission was achieved, between the group of patients treated with Tocilizumab and the group of patients treated with Abatacept. No significative difference were evaluated in the two outcomes [(A) χ2 0, p 0.999; (B) χ20.29, p 0.5]. ABA, Abatacept; TCZ, Tocilizumab.